Atara Biotherapeutics (ATRA) Net Cash Flow (2013 - 2026)

Atara Biotherapeutics has reported Net Cash Flow for 14 years, with the latest figure at -$122000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 98.91% year-over-year to -$122000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.6 million (up 73.52% YoY), and the FY2025 full-year result was -$16.7 million, down 1958.45% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$122000.0, down from $2.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $26.6 million in Q4 2022, with the low at -$44.2 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$5.8 million across 5 years, with a median of -$3.8 million in 2024.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 473.73% — and 2023, when it sank 890.39%.
• Atara Biotherapeutics' Net Cash Flow stood at $26.6 million in 2022, then tumbled by 246.27% to -$38.9 million in 2023, then jumped by 45.0% to -$21.4 million in 2024, then surged by 112.79% to $2.7 million in 2025, then tumbled by 104.45% to -$122000.0 in 2026.
• The last three Net Cash Flow figures came in at -$122000.0 (Q1 2026), $2.7 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.